Neonatal cytogenetic validation demonstrates high accuracy of single-nucleotide polymorphism-based non-invasive prenatal testing: a 4466-case single-center study
Noninvasive prenatal testing using SNP analysis reliably detects Down and Edwards syndromes in a study of 4,466 pregnancies, clarifying which conditions it works best for.
In 4466 high-risk pregnancies, SNP-based NIPT demonstrated high specificity (99.9%) and strong sensitivity for trisomies 18 and 13 but lower sensitivity for T21 (80%), with rare false negatives attributable to low-level mosaicism confirmed by neonatal FISH. This large cytogenetically confirmed dataset strengthens the evidence base for SNP-NIPT performance and clarifies biological limitations.
What the study was
- Study design
- Prospective clinical validation study with cytogenetic confirmation
- Population
- High-risk pregnant women undergoing SNP-based NIPT, 2013–2022, Keio University Hospital
- Sample size
- 4466
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- J Hum Genet
Why it surfaced
Large prospective validation (n=4466) with cytogenetic confirmation is methodologically rigorous and uncommon; fills a gap in SNP-NIPT performance evidence. T21 sensitivity of 80% is lower than expected — clinically important limitation to document.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.